Introduction
============

According to the guidelines from the World Health Organization, gliomas are categorized into grades I to IV. Glioblastoma multiforme (GBM) is classified as grade IV and it is a highly malignant form ([@b1-mmr-22-02-0859],[@b2-mmr-22-02-0859]). GBM has been recognized as the most aggressive type of brain tumor with highly infiltrative ability ([@b3-mmr-22-02-0859]), affecting about \~20,000 people every year in the United States ([@b4-mmr-22-02-0859]). Currently, the treatments for GBM include surgical resection, chemotherapy and radiotherapy ([@b5-mmr-22-02-0859]). However, due to the aggressiveness of gliomas and their resistance to chemotherapy and radiation therapy ([@b6-mmr-22-02-0859],[@b7-mmr-22-02-0859]), the prognosis of GBM is still poor with a median survival time of 12--15 months for patients with GBM ([@b8-mmr-22-02-0859],[@b9-mmr-22-02-0859]). In recent years, targeted therapies, such as combinatorial chemotherapy targeting molecular subgroups and gene and immune therapies, have made important progress in preclinical models ([@b10-mmr-22-02-0859]--[@b12-mmr-22-02-0859]). However, the potential molecular mechanism in the pathogenesis of GBM needs to be further investigated. In order to improve the prognosis of GBM patients, it is important to identify molecular mechanism underlying GBM pathogenesis.

In recent years, a number of studies have investigated the potential molecular mechanisms of GBM. It has been reported that the upregulation and mutations in *EGFR* may be responsible for the resistance of glioma cells to the treatments with chemotherapy and radiation ([@b13-mmr-22-02-0859]--[@b15-mmr-22-02-0859]). Additionally, Annexin-A5 over-activation increases Snail expression level via the PI3K/Akt/NF-κB signaling pathway, which is associated with glioblastoma cells migration and invasion ([@b16-mmr-22-02-0859]). In addition, Siebzehnrubl *et al* ([@b17-mmr-22-02-0859]) indicated that *ZEB1* is linked to tumor chemoresistance and invasion of glioblastoma cells by modulating its downstream effectors, including *c-MYB, MGMT* and *ROBO1*. Nevertheless, the exact molecular mechanism and gene networks underlying GBM progression remain to be fully elucidated.

The present study aimed to identify the potential key nodes and molecular mechanisms associated with the progression of GBM. Co-expression interactions between the identified DEGs were conducted using a protein-protein interaction (PPI) network and several critical genes were identified. In addition, a network module analysis was performed according to the PPI network. In conclusion, the present study may improve the current understanding of the pathogenesis underlying GBM and identified key genes that may represent novel targets for the development of novel treatments of GBM.

Materials and methods
=====================

### Data download

RNA-seq data were downloaded from The Cancer Genome Atlas (TCGA) database ([portal.gdc.cancer.gov/](portal.gdc.cancer.gov/)) ([@b18-mmr-22-02-0859]). The data of 169 GBM samples and 5 normal brain tissue samples were used and analyzed.

### Data preprocessing and DEG analysis

Based on the annotation information contained in the Ensembl database ([asia.ensembl.org/html](asia.ensembl.org/html)) ([@b19-mmr-22-02-0859]), 23,269 protein coding genes were identified. Then, the DEGs between GBM samples and normal samples were screened using edgeR package in R ([@b20-mmr-22-02-0859],[@b21-mmr-22-02-0859]). A P\<0.01 and \|log2 (fc)\| \>4 were selected as the cutoff criteria for the identification of DEGs. In addition, a volcano plot was drawn using the gplots package in R software ([@b22-mmr-22-02-0859]).

### Functional and pathway enrichment analysis of DEGs

To reveal the main functional pathways of GBM, the Database for Annotation, Visualization and Integrated Discovery (DAVID; <http://david.ncifcrf.gov/>) was used to analyze Gene Ontology (GO) terms and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways enriched in the identified DEGs ([@b23-mmr-22-02-0859]). DEG count ≥2 and P\<0.05 were used as cutoff to identify the significant biological functions and signaling pathways.

### PPI network and module analysis of DEGs

The Search Tool for the Retrieval of Interacting Genes/Proteins (STRING) database (<https://string-db.org/>) was used to assess the interacting partners of the DEGs ([@b24-mmr-22-02-0859]), and the PPI network was constructed with a combined score \>0.7. Visualization of the network was performed with Cytoscape (version 3.6.1) software ([@b25-mmr-22-02-0859]). After constructing the PPI network, topology characteristics of the network were analyzed using the Network Analyzer plug-in of Cytoscape software, and degree distribution, distribution of the shortest path, average clustering coefficient and closeness centrality were examined ([@b26-mmr-22-02-0859]). Subsequently, the top 10 significant hub genes or key nodes were identified according to their connectivity degrees by using the CytoHubba tool, a plug-in for Cytoscape ([@b27-mmr-22-02-0859]). The MCODE plug-in was used to analyze the highly interconnected clusters of this network with default parameters ([@b28-mmr-22-02-0859]).

### UALCAN survival analysis

UALCAN ([ualcan.path.uab.edu/](ualcan.path.uab.edu/)) is an interactive web-software that can be used to perform analyses of tumor subgroup gene expression and survival ([@b29-mmr-22-02-0859]). In UALCAN, samples were categorized into two groups: High expression and Low/Medium expression patients. High expression patients refer to the highest quarter of all patients. Low and medium expression patients refer to the remaining three quarters of patients. The P-values from the Kaplan-Meier analysis were based on log-rank. The effects of candidate key gene expression levels on overall survival (OS) were analyzed using UALCAN.

### Sample collection and ethics statement

To determine the expression of hub genes in GBM tissues, samples from 20 patients (age, 26--77 years), including nine males and eleven females, who underwent tumor resection surgery were collected at the Shanghai Ninth People\'s Hospital between September 2010 and March 2018. All patients provided written informed consent, and the study conducted in accordance with the Declaration of Helsinki. In addition, 20 normal brain tissues (used as the control group) were collected from patients who suffered from traumatic brain injury and required internal decompression surgery. After collection, all tissues were frozen in liquid nitrogen and stored at −80°C. All participants in the present study signed informed consents and the study was approved by the Ethics Review Committee of Shanghai Ninth People\'s Hospital.

### RNA extraction and reverse transcription-quantitative (RT-q) PCR

TRIzol (cat. no. 9109; Takara Bio, Inc.) was used to isolate total RNA from each tissue sample according to the manufacturer\'s instructions. Briefly, 2 ml TRIzol was added to brain tissue (100 mg) to prepare homogenate. After obtaining RNA, TE buffer was used to dilute the RNA. Nanodrop software (ND2000C; Gene Company, Ltd.) was used to determine the OD value. A value of OD~260~/OD~280~ within 1.7--2.1 indicated that the extracted RNA was relatively pure. Then, total RNA was reverse transcribed into cDNAs using the PrimeScript RT Master Mix (cat. no. RR036A; Takara Bio, Inc.). RT-qPCR was performed to measure the levels of cDNAs using a SYBR GREEN kit (cat. no. RR420 A; Takara Bio, Inc.). qPCR amplification procedure was performed as follows: Pre-denaturation at 95°C for 30 sec for 1 cycle followed by 40 cycles of 95°C for 5 sec and 60°C for 20 sec. The relative expression level of the five key genes was calculated following comparative CT method, as previously described ([@b30-mmr-22-02-0859]). GAPDH was used to normalize the mRNA expression level. The primer sequences are presented in [Table I](#tI-mmr-22-02-0859){ref-type="table"}.

### Statistical analysis

Experimental data are presented as the mean ± standard error of the mean. All statistical analyses were performed using SPSS 20.0 (IBM, Corp.) and visualized using GraphPad Prism 6.0 (GraphPad Software Inc.). Differences in expression levels between groups were analyzed by unpaired Student\'s t-test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Identification of DEGs

Using P\<0.01 as a cutoff, a total of 1,483 DEGs (954 upregulated genes and 529 downregulated) were identified between GBM and control samples ([Table S1](#SD1-mmr-22-02-0859){ref-type="supplementary-material"}). The volcano plot of DEGs is presented in [Fig. 1](#f1-mmr-22-02-0859){ref-type="fig"}. Each individual dot represents a DEG.

### Functional and pathway enrichment analysis of the DEGs

The GO enrichment analysis results revealed that 954 upregulated DEGs were primarily involved in biological process that included 'anterior/posterior pattern specification', 'embryonic skeletal system morphogenesis', 'sister chromatid cohesion' and 'cell division' ([Fig. 2](#f2-mmr-22-02-0859){ref-type="fig"}). According to the 'cellular components' analysis, DEGs were found to be primarily localized in the nucleus. In addition, the most significantly enriched molecular functions were related to transcriptional activator activity. In addition, as presented in [Fig. 3](#f3-mmr-22-02-0859){ref-type="fig"}, 529 downregulated DEGs were significantly associated with 'chemical synaptic transmission', 'regulation of ion transmembrane transport' and 'γ-aminobutyric acid signaling pathway'. The top five main biological processes enriched in the upregulated and downregulated DEGs are presented in [Tables II](#tII-mmr-22-02-0859){ref-type="table"} and [III](#tIII-mmr-22-02-0859){ref-type="table"}, respectively. The associated signaling pathways significantly enriched in the identified DEGs are presented in [Table IV](#tIV-mmr-22-02-0859){ref-type="table"}. The KEGG pathway analysis indicated that upregulated DEGs were mostly involved in pathways such as 'cell cycle' and 'p53 signaling' pathways, whereas downregulated genes were associated with 'retrograde endocannabinoid signaling', 'GABAergic synapse' and 'glutamatergic synapse'.

### PPI network construction of DEGs

Based on the STRING database and Cytoscape software, PPI networks were constructed with combined scores \>0.7, including 645 nodes and 1,779 edges ([Fig. 4](#f4-mmr-22-02-0859){ref-type="fig"}). Subsequently, the node degree distribution of this network was analyzed using a pattern of power-law according to the topology property ([Fig. 5](#f5-mmr-22-02-0859){ref-type="fig"}). In this network, a degree value \>40 was used as the cutoff criterion for the CytoHubba tool. Finally, 10 DEGs were identified as the hub genes with the highest connectivity degree: cyclin dependent kinase 1 (*CDK1*), centromere protein A (*CENPA*), G protein subunit γ 3 (*GNG3*), BUB1 mitotic checkpoint serine/threonine kinase (*BUB1*), cyclin B2 (*CCNB2*), kinesin family member 2C (*KIF2C*), aurora kinase B (*AURKB*), baculoviral IAP repeat containing 5 (*BIRC5*), cell division cycle associated 8 (*CDCA8*) and BUB1 mitotic checkpoint serine/threonine kinase B (*BUB1B*).

### Module analysis of the PPI network

Generally, biological networks contain several functional modules and they may interact in various biological process ([@b31-mmr-22-02-0859]). In the present study, the top two clusters were identified from the PPI network using MCODE analysis. The most significant cluster involved 35 nodes and 572 edges, and *CDK1, BUB1, BUB1B, CENPA* were highly enriched ([Fig. 6A](#f6-mmr-22-02-0859){ref-type="fig"}). Cluster 2 is presented in [Fig. 6B](#f6-mmr-22-02-0859){ref-type="fig"}, consisting of 24 nodes and 276 edges. Specifically, the hub gene *GNG3* was enriched in cluster 2, which indicated that it may be involved in the pathogenesis of GBM by cooperating with other genes.

### UALCAN survival analysis

UALCAN was used to analyze the OS of 169 patients with GBM based on TCGA data. Briefly, survival analysis indicated that the higher expression of *CENPA* gene was significantly correlated with shorter OS time in GBM patients, whereas the expression of *CDK1, BUB1, BUB1B* and *GNG3* was not correlated with OS ([Fig. 7](#f7-mmr-22-02-0859){ref-type="fig"}).

### Expression of hub genes in GBM

To further verify the expression level of hub genes in GBM samples, RT-qPCR was performed to calculate the mRNA levels of the five hub genes identified in the present study (*CDK1, BUB1, BUB1B, CENPA* and *GNG3*) in GBM samples. As illustrated in [Fig. 8](#f8-mmr-22-02-0859){ref-type="fig"}, the expression of *CDK1, BUB1, BUB1B* and *CENPA* were significantly upregulated in GBM samples compared with normal control tissues. By contrast, the expression level of *GNG3* was higher in the control tissues compared with tumor tissues. The present RT-qPCR results were in line with the aforementioned bioinformatics analysis, suggesting that these key genes may be linked to the molecular mechanism underlying GBM.

Discussion
==========

Glioblastoma multiforme (GBM) is the most common aggressive brain tumor, and is associated with a poor patient survival rate ([@b32-mmr-22-02-0859]). However, the most important challenge in treating GBM is the presence of significant intra-tumor heterogeneity ([@b13-mmr-22-02-0859],[@b33-mmr-22-02-0859],[@b34-mmr-22-02-0859]). Although previous studies have reported numerous potential biomarkers associated with the progression of GBM, the potential molecular mechanism underlying its pathogenesis has not been comprehensively investigated ([@b35-mmr-22-02-0859]--[@b37-mmr-22-02-0859]). In the present study, a total of 1,483 DEGs were identified, containing 954 upregulated genes and 529 downregulated genes. The present results suggested that these DEGs were primarily enriched in cell division, mitotic nuclear division and chemical synaptic transmission. In addition, the upregulated and downregulated genes were related to cell cycle, p53 signaling pathway and synapse. A PPI network was constructed and the highly connected module were identified. After module analysis, several hub genes with higher degree of connectivity were identified, including *CDK1, BUB1, BUB1B, CENPA* and *GNG3*.

In the TCGA database, there were only 5 control samples. Although it is of a smaller size when compared with the 169 GBM samples, it should not have great influence on the results of the present study, as there was relatively little individual difference in the control simples from different patients, whereas the difference was much more evident in tumor samples due to intratumoral heterogeneity between different patients.

*CDK1*, also named cell division control protein 2, is an important cell cycle regulator functioning as a serine/threonine kinase ([@b38-mmr-22-02-0859],[@b39-mmr-22-02-0859]). During G2 and early mitosis, active CDK1-cyclin complexes can phosphorylate various downstream proteins, leading to re-organization of the cytoskeleton, nuclear envelope breakdown and chromosome condensation ([@b40-mmr-22-02-0859],[@b41-mmr-22-02-0859]). Previous studies have reported that downregulation of *CDK1* could inhibit proliferative ability of human glioma cells, while overexpression of *CDK1* contributed to senescence escape of the cells and promoted oncogenesis of human gliomas ([@b42-mmr-22-02-0859]--[@b44-mmr-22-02-0859]). In the present study, *CDK1* was also observed to be significantly upregulated in the module analysis of the PPI network constructed. The present results suggested that *CDK1*, interacting with other genes identified in the present module analysis, may be associated with the progression of GBM by modulating the cell cycle.

In addition, *CDK1, BUB1, BUB1B* and *CENPA* were also identified as key nodes in the current study. *BUB1* and *BUB1B* are spindle assembly checkpoint (SAC) genes that serve as a controller of mitotic checkpoints and chromosome segregation ([@b32-mmr-22-02-0859],[@b45-mmr-22-02-0859]). *BUB1* mRNA was reported to be upregulated in glioma samples and the expression level was positively correlated with glioma grade ([@b46-mmr-22-02-0859]). In addition, *BUB1B* was identified to be enriched in glioblastoma cells and associated with radio-resistance and recurrence of glioblastoma ([@b47-mmr-22-02-0859],[@b48-mmr-22-02-0859]). In accordance with these previous studies, the present study identified that the expression levels of both *BUB1* and *BUB1B* in GBM samples were higher compared with the negative controls. Collectively, accumulating evidence suggested that *BUB1* and *BUB1B* may exert a significant influence on the progression of GBM by regulating mitotic spindle assembly checkpoint and sister chromosome segregation during mitosis. It has been previously reported that SAC inhibition promoted the response of glioblastoma cells to antimitotic drugs and enhanced the efficacy of tumor treating fields, which impair mitosis by disturbing the spindle formation ([@b49-mmr-22-02-0859],[@b50-mmr-22-02-0859]). Therefore, inhibition of *BUB1* or *BUB1B* may be a therapeutic strategy to treat GBM by influencing SAC during the process of cell division. In addition, *CENPA*, which encodes a centromere-associated protein, plays an important role in cell division by directing the assembly of active kinetochores ([@b51-mmr-22-02-0859]). Failure in this process could lead to dysfunction of chromosome segregation, which has been found to be associated with initiation and progression of cancer ([@b52-mmr-22-02-0859]--[@b54-mmr-22-02-0859]). Notably, the present study identified a higher expression level of *CENPA* in brain tissue samples from GBM patients and high levels of *CENPA* were significantly associated with shorter OS. In addition, GO enrichment analyses showed that *CENPA* was involved in the biological function of sister chromatid cohesion, nucleosome assembly and mitotic cytokinesis. The present results suggested that *CENPA* gene may regulate the mitosis of glioma cells by interacting with other genes in the cluster 1, thus suggesting an association with pathogenesis and prognosis in GBM. The present study identified a novel potential target molecule in GBM, and inhibition of *CENPA* may be a novel potential therapeutic strategy for GBM.

The present results showed that *GNG3* may be associated with the GABAergic synapse pathway. *GNG3* is a gene that encodes the γ subunits of G proteins ([@b55-mmr-22-02-0859]), and the disruption of *GNG3* may induce the dysfunction of the GABAB1 receptor signaling pathway ([@b56-mmr-22-02-0859]). Notably, a previous study reported that switching *GABA* catabolism toward γ-hydroxybutyric acid production could suppress glioblastoma cell tumorigenic properties ([@b57-mmr-22-02-0859]). Therefore, it was hypothesized that low expression of *GNG3* may be associated with the pathogenesis of GBM by regulating related signaling pathways ([Table SII](#SD1-mmr-22-02-0859){ref-type="supplementary-material"}). However, further studies are required to confirm the role of *GNG3* in GBM.

Collectively, the present study has identified that several hub genes (*CDK1, BUB1, BUB1B, CENPA* and *GNG3*) were involved in the mechanism of GBM. The present results suggested that *CDK1, BUB1, BUB1B* and *CENPA* may play an essential role in the cell cycle pathway, leading to GBM progression. In addition, *GNG3* was found to be a potential therapeutic target to treat GBM. The present results may provide novel insights into the molecular mechanisms of GBM. Additional studies investigating the hub genes identified in the present study are required to examine their detailed function and interaction in GBM. However, several classical molecular traits, such as IDH1 mutation status, were not analyzed with these hub genes in our study. The authors believe that the IDH mutation analysis for these hub genes, such as CENPA, need to be investigated in the future. Furthermore, it is also appealing to investigate whether these hub genes are regulated by oncogenic mutations of themselves or other genes in the future.
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![Volcano plot of differentially expressed genes in glioblastoma multiform. Black, non-differentially expressed genes; red, significantly upregulated genes; green, significantly downregulated genes (based on \|log 2 FC\|\>4 and P\<0.01). FC, fold-change. FDR, false discovery rate.](MMR-22-02-0859-g00){#f1-mmr-22-02-0859}

![Top 10 Gene Ontology analysis of 954 upregulated differentially expressed genes associated with glioblastoma multiforme. (A) 'Biological Processes', (B) 'Cellular Components' and (C) 'Molecular Function', and (D) KEGG pathway analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-22-02-0859-g01){#f2-mmr-22-02-0859}

![Top 10 Gene Ontology analysis of 529 downregulated differentially expressed genes associated with glioblastoma multiforme. (A) 'Biological Processes', (B) 'Cellular Components' and (C) 'Molecular Function', and (D) KEGG pathway analysis. KEGG, Kyoto Encyclopedia of Genes and Genomes.](MMR-22-02-0859-g02){#f3-mmr-22-02-0859}

![The giant protein-protein interaction network. Key nodes in the network are presented in different colors: Blue stands for the hub genes, red corresponds to the upregulated genes and green corresponds to the downregulated genes in glioblastoma multiforme.](MMR-22-02-0859-g03){#f4-mmr-22-02-0859}

![The topology properties. (A) Distribution of degrees, (B) Average clustering coefficient, (C) Shortest path distribution and (D) Closeness centrality.](MMR-22-02-0859-g04){#f5-mmr-22-02-0859}

![Top 2 modules were extracted from the protein-protein interaction network. Blue stands for the hub genes, red corresponds to the upregulated genes and green corresponds to the downregulated genes in glioblastoma multiforme. (A) Cluster 1 and (B) cluster 2.](MMR-22-02-0859-g05){#f6-mmr-22-02-0859}

![Kaplan-Meier curve of five key genes in patients with GBM. The red lines represent patients with low gene expression, and green lines represent patients with high gene expression. (A) *CDK1*, (B) *BUB1*, (C) *BUB1B*, (D) *CENPA* and (E) *GNG3*. GBM, glioblastoma multiforme. *CDK1*, cyclin dependent kinase 1; *BUB1*, BUB1 mitotic checkpoint serine/threonine kinase; *BUB1B*, BUB1 mitotic checkpoint serine/threonine kinase B; *CENPA*, centromere protein A; *GNG3*, G protein subunit γ 3.](MMR-22-02-0859-g06){#f7-mmr-22-02-0859}

![The mRNA expression of five hub genes in tissues of GBM patients. (A) *CDK1*, (B) *BUB1*, (C) *BUB1B*, (D) *CENPA* and (E) *GNG3*. Expression of these genes was normalized against GAPDH expression. The statistical significance of differences was analyzed by t-test. GBM, glioblastoma multiforme. *CDK1*, cyclin dependent kinase 1; *BUB1*, BUB1 mitotic checkpoint serine/threonine kinase; *BUB1B*, BUB1 mitotic checkpoint serine/threonine kinase B; *CENPA*, centromere protein A; *GNG3*, G protein subunit γ 3.](MMR-22-02-0859-g07){#f8-mmr-22-02-0859}

###### 

Primer sequences for PCR.

  cDNA      Forward primer (5′-3′)   Reverse primer (5′-3′)
  --------- ------------------------ -------------------------
  *CDK1*    CACAAAACTACAGGTCAAGTGG   GAGAAATTTCCCGAATTGCAGT
  *BUB1*    GAAAGCATGAGCAATGGGTAAA   CCACCTGATGCAACTTCTTATG
  *BUB1B*   ATGGGTCCTTCTGGAAACTTAG   GGAATGTAGTGTCAAAAACCCC
  *CENPA*   AAGAGCACACACCTCTTGATAA   CATGTAAGGTGAGGAGATAGGC
  *GNG3*    CGGTGAACAGCACTATGAGTAT   TCACAGTAAGTCATCAGGTCTG
  *GAPDH*   GTGGACCTGACCTGCCGTCTAG   GAGTGGGTGTCGCTGTTGAAGTC

###### 

GO analysis of upregulated genes associated with glioblastoma multiforme.

  Category           Term                                             Count   P-value
  ------------------ ------------------------------------------------ ------- ----------
  GOTERM_BP_DIRECT   GO:0007062\~sister chromatid cohesion            17      8.70E-12
  GOTERM_BP_DIRECT   GO:0051301\~cell division                        26      5.28E-10
  GOTERM_BP_DIRECT   GO:0007067\~mitotic nuclear division             20      2.20E-08
  GOTERM_BP_DIRECT   GO:0007051\~spindle organization                 3       0.026829
  GOTERM_BP_DIRECT   GO:0007094\~mitoticspindle assembly checkpoint   3       0.04073
  GOTERM_CC_DIRECT   GO:0005634\~nucleus                              142     3.58E-13
  GOTERM_CC_DIRECT   GO:0005615\~extracellular space                  51      5.11E-09
  GOTERM_CC_DIRECT   GO:0000777\~condensed chromosome kinetochore     13      9.06E-09
  GOTERM_MF_DIRECT   GO:0043565\~sequence-specific DNA binding        57      5.42E-31
  GOTERM_MF_DIRECT   GO:0003677\~DNA binding                          46      2.76E-04
  GOTERM_MF_DIRECT   GO:0003682\~chromatin binding                    17      2.76E-04

GO, Gene Ontology; BP, 'Biological Process'; CC, 'Cellular Component'; MF, 'Molecular Function'.

###### 

GO analysis of downregulated genes associated with glioblastoma multiforme.

  Category           Term                                                                                                      Count   P-value
  ------------------ --------------------------------------------------------------------------------------------------------- ------- ----------
  GOTERM_BP_DIRECT   GO:0007268\~chemical synaptic transmission                                                                54      1.09E-42
  GOTERM_BP_DIRECT   GO:0034765\~regulation of ion transmembrane transport                                                     18      1.37E-11
  GOTERM_BP_DIRECT   GO:0007269\~neurotransmitter secretion                                                                    12      1.33E-09
  GOTERM_BP_DIRECT   GO:0007187\~G-protein coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger   11      7.02E-09
  GOTERM_BP_DIRECT   GO:0007214\~gamma-aminobutyric acid signaling pathway                                                     8       7.68E-08
  GOTERM_CC_DIRECT   GO:0005886\~plasma membrane                                                                               162     7.00E-26
  GOTERM_CC_DIRECT   GO:0005887\~integral component of plasma membrane                                                         85      4.55E-23
  GOTERM_CC_DIRECT   GO:0045211\~postsynaptic membrane                                                                         32      1.74E-19
  GOTERM_MF_DIRECT   GO:0005230\~extracellular ligand-gated ion channel activity                                               11      1.99E-10
  GOTERM_MF_DIRECT   GO:0004890\~GABA-A receptor activity                                                                      9       6.42E-10
  GOTERM_MF_DIRECT   GO:0005516\~calmodulin binding                                                                            17      3.29E-07

GO, Gene Ontology; BP, biological process; CC, cellular component; MF, molecular function.

###### 

Results of KEGG pathway analysis.

  A, Upregulated genes                                            
  --------------------------------------------------- ----------- -------------
  hsa04110: Cell cycle                                12          3.26E-07
  hsa05322: Systemic lupus erythematosus              9           2.49E-04
  hsa04115: p53 signaling pathway                     6           0.001428
  hsa04512: ECM-receptor interaction                  6           0.004496
  hsa05202: Transcriptional misregulation in cancer   8           0.004710
                                                                  
  **B, Downregulated genes**                                      
                                                                  
  **Term**                                            **Count**   **P-value**
                                                                  
  hsa04080: Neuroactive ligand-receptor interaction   44          5.35E-28
  hsa04723: Retrograde endocannabinoid signaling      20          4.27E-14
  hsa04020: Calcium signaling pathway                 24          3.72E-13
  hsa04727: GABAergic synapse                         15          7.40E-10
  hsa04724: Glutamatergic synapse                     15          3.76E-08

KEGG, Kyoto Encyclopedia of Genes and Genomes.
